ArticleCureus2026
Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome Associated With Relugolix Therapy for Giant Uterine Fibroids and Anemia: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological condition characterized by reversible vasogenic edema. Reversible cerebral vasoconstriction syndrome (RCVS) is a disorder characterized by segmental narrowing of the cerebral arteries that causes severe headaches. We report a case of PRES and RCVS development in a 52-year-old woman treated with a gonadotropin-releasing hormone antagonist, relugolix, and oral iron supplementation for uterine fibroids and iron deficiency anemia. In this case, relugolix may have contributed to the onset of PRES and RCVS through estrogen suppression and the resulting endothelial dysfunction. Additionally, gradual treatment of anemia over two months with oral iron alone may have played a role in this case, given that increased intravascular volume and viscosity can precipitate vascular injury and vasoconstriction. To our knowledge, this represents the first reported case of concurrent PRES and RCVS associated with relugolix therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.